Snapshot from Sep 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Business equity offering

Addex raises USD 2.8 million via ATM offering

Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The capital raise provides Addex with additional funding to support its clinical programs, extending its cash runway into late 2027. This modest offering may slightly dilute existing shareholders but signals continued financial support from investors, potentially stabilizing the stock.

Biopharmaceuticals

Addex Therapeutics, a clinical-stage biopharmaceutical company, announced on August 26, 2026, that it raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 American Depositary Shares (ADSs) representing 52,544,280 shares, under its At the Market (ATM) offering agreement with H.C. Wainwright & Co. The proceeds extend the company's cash runway to the fourth quarter of 2027. Following the sale, outstanding shares increased to 210,292,217, while issued shares remained at 218,654,496. Addex continues to develop allosteric modulators for neurological disorders, with lead candidate dipraglurant and partnerships including Indivior.

100 Addex Therapeutics raised
80 Addex Therapeutics extended cash runway
stock
Addex raised USD 2.8 million through an ATM offering, extending its cash runway to Q4 2027. This provides near-term financial stability for its clinical programs.
Importance 100.0 Sentiment 10.0
priv
H.C. Wainwright acted as the sales agent for the ATM offering, facilitating the capital raise for Addex.
Importance 80.0 Sentiment 10.0
stock
Indivior is a partner of Addex, having selected a GABAB PAM candidate for development; the capital raise does not directly affect Indivior.
Importance 20.0 Sentiment 0.0
curr
The offering was denominated in USD, with gross proceeds of USD 2.8 million.
Importance 10.0 Sentiment 0.0
priv
Addex holds a 20% equity interest in Neurosterix, which is advancing allosteric modulator programs; the offering does not directly impact Neurosterix.
Importance 10.0 Sentiment 0.0
priv
Addex has invested in Stalicla, a private Swiss company; the offering does not directly affect Stalicla.
Importance 10.0 Sentiment 0.0
exch
Addex shares are listed on the SIX Swiss Exchange; the offering may influence trading activity but does not directly affect the exchange.
Importance 10.0 Sentiment 0.0
exch
Addex ADSs are listed on Nasdaq; the offering may influence trading activity but does not directly affect the exchange.
Importance 10.0 Sentiment 0.0
curr
The offering proceeds were also reported in CHF, equivalent to CHF 2.2 million.
Importance 10.0 Sentiment 0.0
per
Tim Dyer is the CEO of Addex and is listed as a contact for the announcement.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.